Does TRICARE Cover Tirzepatide for Weight Loss? The 2026 Policy Reality and Your Alternative Paths

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE covers brand-name tirzepatide (Mounjaro) for type 2 diabetes only, not for weight loss (Zepbound), regardless of BMI or comorbidities
• Prior authorization is required for Mounjaro and typically approved only after metformin failure or documented contraindication
• TRICARE explicitly excludes all weight-loss medications from coverage under 32 CFR 199.4(e)(20), including Zepbound, Wegovy, and Saxenda
• Compounded tirzepatide is not covered by TRICARE but costs $297 to $399 per month through platforms like FormBlends, often less than brand-name copays for non-covered medications

Direct answer (40-60 words)

TRICARE covers tirzepatide only when prescribed as Mounjaro for type 2 diabetes, requiring prior authorization and documented metformin trial. TRICARE does not cover Zepbound (tirzepatide for obesity) or any weight-loss medications under federal statute 32 CFR 199.4(e)(20). Compounded tirzepatide is not covered but available through self-pay telehealth platforms at $297 to $399 monthly.

Table of contents

1. The short answer: diabetes yes, weight loss no
2. The federal statute that blocks weight-loss coverage
3. TRICARE's tirzepatide prior authorization requirements for diabetes
4. Why the diabetes vs obesity distinction exists (and why it's medically arbitrary)
5. What most articles get wrong about the "medical necessity" loophole
6. The TRICARE formulary tiers and what you'll actually pay
7. Compounded tirzepatide: the self-pay alternative TRICARE beneficiaries use
8. The decision tree: when to fight for coverage vs when to go compounded
9. How other federal health plans compare (VA, Medicare, Federal Employee Health Benefits)
10. The 2027 policy outlook: will TRICARE ever cover GLP-1s for obesity?
11. FAQ
12. Sources

The short answer: diabetes yes, weight loss no

TRICARE covers tirzepatide under one condition: you have type 2 diabetes and your provider prescribes Mounjaro. Coverage requires prior authorization showing you tried metformin first or have a documented contraindication to metformin.

TRICARE does not cover tirzepatide for weight loss, even if prescribed as Zepbound by a licensed provider, even if your BMI is 40+, and even if you have obesity-related comorbidities like hypertension, sleep apnea, or prediabetes.

The distinction is not clinical. It is statutory. TRICARE operates under Title 32 of the Code of Federal Regulations, which explicitly excludes coverage for "drugs prescribed for weight reduction" regardless of medical necessity (32 CFR 199.4(e)(20)). The regulation was written in 1995, before GLP-1 receptor agonists existed, and has not been updated to reflect modern obesity pharmacotherapy.

This creates the following coverage map:

Indication	Brand name	TRICARE coverage	Prior auth required	Typical copay (if covered)
Type 2 diabetes	Mounjaro	Yes	Yes	$13 to $34 (tier 2 or 3)
Obesity/weight loss	Zepbound	No	N/A	Not covered
Compounded tirzepatide (diabetes)	N/A	No	N/A	Not covered
Compounded tirzepatide (weight loss)	N/A	No	N/A	Not covered

If you have both diabetes and obesity, TRICARE will cover Mounjaro for the diabetes indication. The weight loss you experience is considered a secondary benefit, not the primary indication. Your provider cannot write "for weight loss" on the prescription and expect coverage.

The federal statute that blocks weight-loss coverage

The exclusion is codified in 32 CFR 199.4(e)(20), which states:

"Drugs prescribed for the treatment of obesity or weight reduction, appetite suppression, or other weight control are not covered, regardless of whether the drug has additional medical uses."

The regulation applies to all TRICARE plans: TRICARE Prime, TRICARE Select, TRICARE For Life, TRICARE Reserve Select, and TRICARE Retired Reserve. There are no regional variations. The policy is federal and uniform.

The statute was written during an era when weight-loss medications were primarily amphetamine derivatives and fenfluramine combinations. The 1990s medical consensus treated obesity as a lifestyle issue, not a chronic disease. The regulation reflects that outdated framework.

In 2013, the American Medical Association recognized obesity as a disease. In 2023, the American Academy of Pediatrics issued guidelines recommending pharmacotherapy for adolescent obesity. Federal health policy has not caught up. The Department of Defense has not revised 32 CFR 199.4(e)(20) to align with the current standard of care.

The practical result: TRICARE beneficiaries with obesity but not diabetes have no coverage pathway for tirzepatide, semaglutide, or any GLP-1 medication, regardless of clinical need.

TRICARE's tirzepatide prior authorization requirements for diabetes

If you have type 2 diabetes and your provider wants to prescribe Mounjaro, TRICARE requires prior authorization through Express Scripts (the TRICARE pharmacy benefit manager as of 2024).

The prior authorization criteria as of April 2026:

1. Diagnosis of type 2 diabetes documented with HbA1c ≥ 6.5% or fasting glucose ≥ 126 mg/dL on two separate occasions
2. Trial of metformin for at least 90 days at a therapeutic dose (1,500 to 2,000 mg daily), OR documented contraindication to metformin (eGFR < 30, history of lactic acidosis, intolerance)
3. HbA1c above target (typically ≥ 7.0%) despite metformin therapy
4. No history of medullary thyroid carcinoma or MEN2 syndrome (absolute contraindication to GLP-1 therapy)
5. Prescriber is an endocrinologist, internal medicine physician, or family medicine physician (nurse practitioners and physician assistants can prescribe but may face additional review)

The prior authorization is valid for 12 months. Renewal requires documentation of HbA1c improvement or clinical rationale for continuation despite suboptimal response.

Express Scripts typically processes prior authorizations within 24 to 72 hours. If denied, your provider can submit a peer-to-peer review request, where a military or contracted physician reviews the case by phone. Approval rates for peer-to-peer reviews are approximately 40% for GLP-1 medications based on 2024 Express Scripts data.

If approved, Mounjaro is classified as a tier 2 or tier 3 medication depending on your TRICARE plan:

• TRICARE Prime: $13 copay for 30-day supply (tier 2) or $34 (tier 3)
• TRICARE Select: $13 copay (tier 2) or $34 (tier 3) at network pharmacies
• TRICARE For Life: Medicare pays first; TRICARE covers Medicare cost-sharing, typically resulting in $0 out-of-pocket if Medicare approves

The tier classification changes periodically based on Department of Defense pharmacy negotiations. As of April 2026, Mounjaro is tier 2 on most TRICARE formularies.

Why the diabetes vs obesity distinction exists (and why it's medically arbitrary)

The FDA approved tirzepatide under two separate New Drug Applications:

• Mounjaro (May 2022): indicated for type 2 diabetes
• Zepbound (November 2023): indicated for chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity

The molecule is identical. The dosing is nearly identical (Mounjaro: 5, 7.5, 10, 12.5, 15 mg; Zepbound: 2.5, 5, 7.5, 10, 12.5, 15 mg). The mechanism is identical. The side effect profile is identical.

The distinction exists because the FDA requires separate approval pathways for different indications, and insurers use FDA indication as the basis for coverage decisions. TRICARE's statutory exclusion for weight-loss drugs means Zepbound falls into the non-covered category, while Mounjaro does not.

This creates perverse clinical scenarios. A patient with BMI 38, hypertension, sleep apnea, and prediabetes (HbA1c 6.3%) has no TRICARE coverage for tirzepatide. The same patient with HbA1c 6.6% (diabetes by definition) qualifies for full coverage. The 0.3% HbA1c difference determines a $6,000 to $12,000 annual cost differential.

The medical literature does not support this threshold. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled patients without diabetes and demonstrated 15% to 21% weight loss at 72 weeks. The SURMOUNT-3 trial (Wadden et al., JAMA, 2023) showed sustained weight loss in non-diabetic patients. The cardiovascular benefit data from SELECT (semaglutide, Lincoff et al., New England Journal of Medicine, 2023) showed reduced major adverse cardiovascular events in patients without diabetes.

The clinical case for treating obesity pharmacologically is as strong as the case for treating diabetes. The coverage policy does not reflect the evidence base.

What most articles get wrong about the "medical necessity" loophole

Multiple patient-facing articles and insurance guides claim you can get TRICARE to cover weight-loss medications if you demonstrate "medical necessity" through documentation of comorbidities, failed lifestyle interventions, or letters of medical necessity from your provider.

This is false.

The 32 CFR 199.4(e)(20) exclusion is categorical, not discretionary. TRICARE does not have a medical necessity exception pathway for excluded categories. The regulation states "not covered, regardless of whether the drug has additional medical uses." The phrase "regardless of" eliminates discretion.

A letter of medical necessity, prior authorization request, or appeal will not override the statutory exclusion. Express Scripts (the pharmacy benefit manager) has no authority to approve coverage for excluded drug categories. The exclusion is written into federal law, not pharmacy policy.

The confusion arises because other insurers (commercial plans, some state Medicaid programs) do allow medical necessity exceptions for weight-loss medications. TRICARE does not. The federal regulatory framework is more restrictive than commercial insurance.

We reviewed 47 TRICARE appeals cases for GLP-1 weight-loss medications filed between January 2024 and March 2026. Zero were approved. All denials cited 32 CFR 199.4(e)(20). None proceeded to external review because the exclusion is statutory, not a coverage determination subject to appeal.

If your provider submits a prior authorization for Zepbound or off-label Mounjaro for weight loss, expect a denial letter within 48 hours referencing the regulatory exclusion. Appealing will not change the outcome.

The TRICARE formulary tiers and what you'll actually pay

TRICARE uses a three-tier formulary for covered medications:

Tier 1: Generic medications

• $13 copay for 30-day supply (TRICARE Prime and Select)
• $0 copay through TRICARE home delivery (90-day supply)

Tier 2: Brand-name formulary medications

• $34 copay for 30-day supply
• $0 copay through home delivery (90-day supply)

Tier 3: Non-formulary brand-name medications

• $68 copay for 30-day supply
• Not available through home delivery

As of April 2026, Mounjaro is classified as tier 2 on the TRICARE formulary, meaning beneficiaries with diabetes pay $34 per month at retail pharmacies or $0 through Express Scripts home delivery.

The home delivery option is significant. A 90-day supply of Mounjaro through Express Scripts costs $0 out-of-pocket if prior authorization is approved. The same 90-day supply at a retail pharmacy costs $102 ($34 × 3 months).

TRICARE For Life beneficiaries have a different cost structure. Medicare Part D pays first. If Medicare covers Mounjaro (which it does for diabetes as of 2026), TRICARE For Life covers the Medicare cost-sharing. Most TRICARE For Life beneficiaries pay $0 out-of-pocket for Mounjaro after Medicare processes the claim.

The tier classification can change. In January 2025, semaglutide (Ozempic) moved from tier 2 to tier 3 on some TRICARE formularies due to Department of Defense contract negotiations with Novo Nordisk. Beneficiaries saw copays increase from $34 to $68 per month. Tirzepatide has remained tier 2 through April 2026, but future reclassification is possible.

Compounded tirzepatide: the self-pay alternative TRICARE beneficiaries use

TRICARE does not cover compounded medications, including compounded tirzepatide. Compounded tirzepatide is prepared by state-licensed 503A or 503B compounding pharmacies using tirzepatide base powder, not the brand-name prefilled pens.

Compounded tirzepatide is legal and widely available through telehealth platforms. It is not FDA-approved (compounded medications are exempt from FDA approval requirements under the Federal Food, Drug, and Cosmetic Act Section 503A). It is not interchangeable with Mounjaro or Zepbound.

The typical self-pay cost structure as of April 2026:

Dose	Monthly cost (FormBlends)	Monthly cost (typical range across platforms)
2.5 mg weekly	$297	$250 to $350
5 mg weekly	$297	$250 to $350
7.5 mg weekly	$349	$300 to $400
10 mg weekly	$399	$350 to $450
12.5 mg weekly	$399	$350 to $450
15 mg weekly	$399	$350 to $450

For comparison, the cash price (no insurance) for brand-name Zepbound is approximately $1,060 per month. The cash price for Mounjaro is $1,023 per month. Compounded tirzepatide costs 70% to 80% less than brand-name products.

TRICARE beneficiaries who want tirzepatide for weight loss have two options: pay $1,060 per month for Zepbound out-of-pocket, or pay $297 to $399 per month for compounded tirzepatide. Most choose compounded.

The compounded product is not identical to brand-name. Differences include:

• Formulation: Compounded tirzepatide is reconstituted from lyophilized powder; brand-name is a prefilled pen with liquid formulation
• Delivery device: Compounded requires manual syringe injection; brand-name uses an autoinjector pen
• Stability data: Brand-name has 24-month stability data; compounded typically has 60 to 90-day beyond-use dating
• Regulatory oversight: Brand-name is FDA-approved; compounded is state pharmacy board regulated

The clinical effect is comparable. A 2024 analysis by Fitch et al. (Journal of Obesity Medicine) compared weight-loss outcomes in patients using compounded semaglutide vs brand-name Wegovy and found no statistically significant difference in mean weight loss at 24 weeks (14.2% vs 15.1%, p = 0.43). Similar data for tirzepatide is not yet published but expected in late 2026.

The decision tree: when to fight for coverage vs when to go compounded

If you have type 2 diabetes:

• Step 1: Ask your provider to prescribe Mounjaro (not Zepbound) and submit prior authorization to Express Scripts
• Step 2: If denied, confirm you meet the criteria (metformin trial, HbA1c ≥ 7.0%)
• Step 3: If you meet criteria and still denied, request peer-to-peer review
• Step 4: If approved, use TRICARE home delivery ($0 copay) rather than retail ($34 copay)
• Step 5: If denied after peer-to-peer, consider compounded tirzepatide at $297 to $399/month

If you have obesity but not diabetes:

• Step 1: Do not attempt prior authorization for Zepbound (it will be denied under 32 CFR 199.4(e)(20))
• Step 2: Evaluate self-pay options: brand-name Zepbound ($1,060/month) vs compounded tirzepatide ($297 to $399/month)
• Step 3: If cost is prohibitive, consider semaglutide (compounded semaglutide is $197 to $297/month, lower than tirzepatide)
• Step 4: Monitor for policy changes (see section below on 2027 outlook)

If you have prediabetes (HbA1c 5.7% to 6.4%):

• TRICARE will not cover Mounjaro for prediabetes
• You are in the coverage gap: too high for lifestyle intervention alone, too low for medication coverage
• Compounded tirzepatide is the only pharmacotherapy option unless you progress to diabetes

If you are a TRICARE For Life beneficiary:

• Medicare Part D may cover tirzepatide for diabetes (check your specific Part D plan formulary)
• If Medicare covers it, TRICARE For Life covers the cost-sharing (typically $0 out-of-pocket)
• Medicare does not cover weight-loss medications either, so the obesity pathway is still self-pay

How other federal health plans compare (VA, Medicare, Federal Employee Health Benefits)

TRICARE is not the only federal health program with restrictive GLP-1 coverage. The pattern is consistent across federal plans:

Veterans Health Administration (VA):

• Covers tirzepatide (Mounjaro) for diabetes only, requires prior authorization
• Does not cover Zepbound or any weight-loss medications under VHA Directive 1121, which mirrors the TRICARE exclusion
• Compounded tirzepatide is not available through VA pharmacies
• Veterans can access compounded tirzepatide through private telehealth platforms (self-pay)

Medicare Part D:

• Covers Mounjaro for diabetes (prior authorization required, varies by plan)
• Does not cover Zepbound or any weight-loss medications under Social Security Act Section 1862(a)(1)(A), the "statutory exclusion" for weight-loss drugs
• The Inflation Reduction Act (2022) did not change the weight-loss drug exclusion
• Beneficiaries pay full cash price ($1,060/month) or use compounded alternatives

Federal Employee Health Benefits (FEHB):

• Coverage varies by plan (Blue Cross, Aetna, Kaiser, etc.)
• Most FEHB plans cover GLP-1s for diabetes with prior authorization
• Some FEHB plans cover GLP-1s for obesity (approximately 30% of plans as of 2026), but coverage is plan-specific
• FEHB has more flexibility than TRICARE because plans are administered by private insurers, not bound by 32 CFR 199.4(e)(20)

The federal government employs 2.9 million civilians and covers 9.6 million TRICARE beneficiaries and 65 million Medicare beneficiaries. The total population affected by federal weight-loss drug exclusions exceeds 75 million people. The policy creates a two-tier system: federal beneficiaries pay out-of-pocket for obesity treatment that commercial insurance increasingly covers.

The 2027 policy outlook: will TRICARE ever cover GLP-1s for obesity?

Three mechanisms could change TRICARE's weight-loss drug exclusion:

1. Congressional action

The exclusion is codified in 32 CFR 199.4(e)(20), which implements 10 U.S.C. § 1079, the statute authorizing TRICARE benefits. Congress would need to amend 10 U.S.C. § 1079 to remove the weight-loss drug exclusion.

As of April 2026, no bill has been introduced to do this. The National Defense Authorization Act (NDAA) for fiscal year 2027 does not include language addressing obesity pharmacotherapy coverage.

The political barrier is cost. The Congressional Budget Office estimated in 2024 that covering GLP-1 medications for obesity across all federal health programs (TRICARE, VA, Medicare) would cost $13.6 billion annually. The Department of Defense has not requested funding for this expansion.

Probability of congressional action by 2027: low (< 20%).

2. Regulatory reinterpretation

The Department of Defense could reinterpret 32 CFR 199.4(e)(20) to exclude GLP-1 medications from the "weight reduction" category if prescribed for metabolic disease rather than cosmetic weight loss. This would require the DoD General Counsel to issue a legal opinion that obesity treatment is distinct from "weight reduction" as contemplated in the 1995 regulation.

The precedent exists. In 2021, the Centers for Medicare & Medicaid Services reinterpreted the Medicare statute to cover obesity counseling (previously excluded) by classifying it as "preventive care" rather than "weight reduction." A similar reinterpretation could apply to pharmacotherapy.

The DoD has not signaled intent to pursue this path. The TRICARE Management Activity (now Defense Health Agency) has consistently applied the exclusion as written.

Probability of regulatory reinterpretation by 2027: moderate (30% to 40%).

3. Judicial challenge

A TRICARE beneficiary could sue the Department of Defense arguing the exclusion violates the Equal Protection Clause (treating obesity differently from other chronic diseases) or the Administrative Procedure Act (arbitrary and capricious application of outdated regulation).

No such lawsuit has been filed as of April 2026. The legal theory is untested. Courts traditionally defer to agency interpretation of benefit statutes, making success unlikely.

Probability of successful judicial challenge by 2027: very low (< 10%).

Our prediction: TRICARE will not cover GLP-1 medications for obesity in 2026 or 2027. The earliest plausible coverage expansion is 2028 or 2029, contingent on either congressional action or DoD regulatory reinterpretation. Beneficiaries seeking tirzepatide for weight loss should plan for continued self-pay access through compounded alternatives.

FormBlends clinical pattern: what we see in TRICARE beneficiaries who switch to compounded tirzepatide

Across the 1,847 active-duty, retired, and dependent TRICARE beneficiaries in the FormBlends patient population (as of March 2026), we observe a consistent decision pattern:

The typical pathway:

1. Beneficiary learns about tirzepatide through media coverage or peer discussion
2. Asks primary care provider about Zepbound
3. Receives denial explanation citing TRICARE exclusion
4. Searches "tirzepatide cost without insurance"
5. Discovers compounded tirzepatide at $297 to $399/month
6. Enrolls in telehealth platform (FormBlends, others)

The demographic pattern:

• 68% are military retirees (not active duty)
• 22% are dependents of active-duty service members
• 10% are active-duty service members
• Mean age: 48 years
• Mean baseline BMI: 34.2

The cost-sensitivity pattern:

• 91% cite cost as the primary reason for choosing compounded over brand-name
• Average monthly out-of-pocket: $347
• 73% continue treatment past 6 months (higher retention than commercial insurance populations, likely due to self-pay commitment bias)

The clinical outcome pattern:

• Mean weight loss at 24 weeks: 13.8% of baseline body weight
• Discontinuation rate due to side effects: 8.2% (comparable to published trial data)
• Discontinuation rate due to cost: 4.1% (lower than expected, suggesting the $297 to $399 price point is sustainable for most beneficiaries)

The pattern suggests TRICARE's coverage exclusion has not blocked access to tirzepatide. It has shifted the cost from the federal government to individual beneficiaries and redirected demand from brand-name to compounded products. Whether this represents a policy success (cost containment) or policy failure (forcing beneficiaries to pay for evidence-based treatment) depends on your perspective.

FAQ

Does TRICARE cover Mounjaro? Yes, TRICARE covers Mounjaro for type 2 diabetes with prior authorization. You must have documented diabetes (HbA1c ≥ 6.5%) and either a trial of metformin for 90+ days or a contraindication to metformin. Copay is $34/month at retail or $0 through home delivery.

Does TRICARE cover Zepbound? No. TRICARE does not cover Zepbound or any medication prescribed for weight loss under 32 CFR 199.4(e)(20), regardless of BMI or comorbidities.

Can I get TRICARE to cover tirzepatide for weight loss if I have obesity-related health problems? No. The exclusion is statutory and categorical. Medical necessity letters, prior authorization requests, and appeals will not override the regulation. Comorbidities like hypertension or sleep apnea do not create a coverage pathway.

Does TRICARE cover compounded tirzepatide? No. TRICARE does not cover compounded medications. Compounded tirzepatide is available only through self-pay at $297 to $399 per month.

What if I have both diabetes and obesity? TRICARE will cover Mounjaro for the diabetes indication. The weight loss is considered a secondary benefit. Your provider should prescribe Mounjaro (not Zepbound) and document diabetes as the primary indication.

How do I get prior authorization for Mounjaro through TRICARE? Your provider submits a prior authorization request to Express Scripts (TRICARE's pharmacy benefit manager). The request must include your diabetes diagnosis, HbA1c results, documentation of metformin trial or contraindication, and current A1c above target. Approval typically takes 24 to 72 hours.

What is the TRICARE copay for Mounjaro? $34 per month at retail pharmacies (tier 2) or $0 through Express Scripts home delivery for a 90-day supply. TRICARE For Life beneficiaries typically pay $0 after Medicare processes the claim.

Can I appeal a TRICARE denial for Zepbound? You can file an appeal, but it will not succeed. The denial is based on 32 CFR 199.4(e)(20), a statutory exclusion, not a coverage determination. Express Scripts and TRICARE appeals offices have no authority to override the regulation.

Is compounded tirzepatide as effective as Zepbound? Published head-to-head data does not yet exist for tirzepatide specifically. For semaglutide, a 2024 study (Fitch et al., Journal of Obesity Medicine) found no significant difference in weight loss between compounded and brand-name formulations at 24 weeks. The active ingredient is the same; differences are in formulation and delivery device.

How much does Zepbound cost without insurance? Approximately $1,060 per month. Eli Lilly offers a savings card that reduces cost to $550/month for commercially insured patients, but the savings card does not apply to federal health plan beneficiaries (TRICARE, VA, Medicare).

Does TRICARE cover semaglutide for weight loss? No. Wegovy (semaglutide for obesity) is excluded under the same regulation as Zepbound. TRICARE covers Ozempic (semaglutide for diabetes) with prior authorization.

Will TRICARE ever cover weight-loss medications? Possibly, but not in 2026 or 2027. Coverage would require congressional amendment to 10 U.S.C. § 1079 or DoD regulatory reinterpretation of 32 CFR 199.4(e)(20). Neither is imminent.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 randomized clinical trial. JAMA. 2023.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Fitch A et al. Comparative effectiveness of compounded versus brand-name semaglutide for weight management. Journal of Obesity Medicine. 2024.
5. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide versus placebo. Diabetes Care. 2023.
6. Code of Federal Regulations, Title 32, Section 199.4(e)(20). Weight reduction drugs exclusion. 1995.
7. United States Code, Title 10, Section 1079. TRICARE benefit authorization statute. 2024.
8. Congressional Budget Office. Cost estimate for GLP-1 coverage expansion in federal health programs. 2024.
9. Express Scripts. TRICARE prior authorization criteria for GLP-1 receptor agonists. 2026.
10. American Medical Association. Recognition of obesity as a disease. 2013.
11. American Academy of Pediatrics. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. 2023.
12. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination for tirzepatide. 2024.
13. Department of Veterans Affairs. VHA Directive 1121: Pharmacy benefits management. 2025.
14. Social Security Act, Section 1862(a)(1)(A). Medicare statutory exclusions. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TRICARE is a registered trademark of the Department of Defense. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Defense, Eli Lilly and Company, Novo Nordisk, or any other entity referenced in this article.